Showing results (181-190 of 192) with videos related to
Sort By:
Pageof 20
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.European Journal of Cancer (Oxford, England : 1990)|March 29, 2017
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trialsMartin D Berger, Shinichi Yamauchi, Shu Cao, et al.Plos One|December 14, 2011
Genome-scale screen for DNA methylation-based detection markers for ovarian cancerMihaela Campan, Melissa Moffitt, Sahar Houshdaran, et al.The Prostate|January 16, 2016
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growthBrian R Hu, Adrian S Fairey, Anisha Madhav, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2015
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyGregory A Yanik, Judith G Villablanca, John M Maris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and PrognosisAraz Marachelian, Judith G Villablanca, Cathy W Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Susan Groshen, Julie R Park, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell LymphomaKevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.Cell Metabolism|June 23, 2015
A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and HealthspanSebastian Brandhorst, In Young Choi, Min Wei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2021
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT ConsortiumSteven G DuBois, M Meaghan Granger, Susan Groshen, et al.Pageof 20